$904 Million is the total value of Casdin Capital, LLC's 40 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EQRX INC | $87,751,425 | +19.4% | 39,527,669 | 0.0% | 9.71% | +51.2% | ||
| RVMD | REVOLUTION MEDICINES INC | $50,100,800 | +3.5% | 1,810,000 | 0.0% | 5.54% | +31.1% | |
| SOMALOGIC INC | $30,124,217 | +3.5% | 12,604,275 | 0.0% | 3.33% | +31.1% | ||
| DNLI | DENALI THERAPEUTICS INC | $26,819,000 | -30.1% | 1,300,000 | 0.0% | 2.97% | -11.5% | |
| TENAYA THERAPEUTICS INC | $16,272,511 | -56.6% | 6,381,377 | 0.0% | 1.80% | -45.0% | ||
| BEAM | BEAM THERAPEUTICS INC | $13,708,500 | -24.7% | 570,000 | 0.0% | 1.52% | -4.7% | |
| GENEDX HOLDINGS CORP | $11,267,660 | -38.9% | 3,095,511 | 0.0% | 1.25% | -22.6% | ||
| 2SEVENTY BIO INC | $7,933,739 | -61.3% | 2,023,913 | 0.0% | 0.88% | -50.9% | ||
| IPSC | CENTURY THERAPEUTICS INC | $6,412,760 | -36.7% | 3,206,380 | 0.0% | 0.71% | -19.8% | |
| FATE | FATE THERAPEUTICS INC | $4,346,000 | -55.5% | 2,050,000 | 0.0% | 0.48% | -43.6% | |
| PRIME MEDICINE INC | $3,502,850 | -34.9% | 367,175 | 0.0% | 0.39% | -17.4% | ||
| FLDM | STANDARD BIOTOOLS INC | $3,480,000 | +50.3% | 1,200,000 | 0.0% | 0.38% | +90.6% | |
| SANA | SANA BIOTECHNOLOGY INC | $2,902,500 | -35.1% | 750,000 | 0.0% | 0.32% | -17.9% | |
| GLUE | MONTE ROSA THERAPEUTICS INC | $2,447,125 | -30.1% | 510,882 | 0.0% | 0.27% | -11.4% | |
| EXSCIENTIA PLCads | $966,828 | -23.6% | 213,900 | 0.0% | 0.11% | -3.6% | ||
| LIANBIOsponsored ads | $307,558 | -34.6% | 206,415 | 0.0% | 0.03% | -17.1% | ||
| KRON | KRONOS BIO INC | $160,991 | -24.4% | 123,839 | 0.0% | 0.02% | -5.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.